Interviews

In an exclusive interview, Generics Bulletin spoke to a trio of experts who argue that biosimilar cell and gene therapies are technically within reach but demand unprecedented regulatory clarity, manufacturing evolution and economic alignment before they become reality.

Axplora made waves with a recent announcement that the API specialist’s total investments for 2025 would exceed €100m. Anant Barbadikar, co-president of the firm’s PharmaZell business unit, explains how the firm’s strategy is evolving and why he believes the future of pharma remains small-molecule.

In the wake of recent FDA guidance on streamlining the registration pathway for biosimilars, Organon’s head of US biosimilars, Jon Martin, talks to Generics Bulletin about how the company is re-evaluating the market landscape.

In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”

With another regulator now considering the removal of clinical efficacy trials for biosimilars, BioPharmaSpec’s technical director Richard Easton paints the picture of data-powered biosimilarity assessment.

With the work undertaken by non-governmental organization International Health Partners to provide access to vital medicines more important than ever, the organization talks to Generics Bulletin about how its work is growing and how companies in the off-patent sector can get involved.

As the US biosimilars market enters its second decade, Cencora’s director of biosimilar commercialization Dennis Nelson talks to Generics Bulletin about the progress made so far, as well as fresh regulatory and commercial developments on the horizon.

Watch now as Adalvo CEO Anil Okay shares with Citeline his perspectives on the rapidly-growing European B2B’s recent acquisition by private equity firm EQT. Find out what it means for the business, and how it may reflect wider pharma trends, in this insightful video interview.

In a detailed interview, Aurobindo’s European CEO Venugopalan Muralidharan – Murali – explains how the firm is increasingly focusing on complex products such as injectables and biosimilars, as well as eyeing upcoming opportunities such as GLP-1s and ADCs, while also remaining open to potential M&A.

Generics Bulletin editor Dave Wallace talks to John Murphy III, president and CEO of the US Association for Accessible Medicines, about the association’s latest annual savings report and key topics affecting the US off-patent market.

After launching two biosimilars and acquiring another leading marketed product in a little over a year, Accord Biopharma has made a major push into US biosimilars. Accord US president Chrys Kokino explains to Generics Bulletin how the firm is seeking to become the market leader.

Launching its new manufacturing site in New Jersey will help bring Biocon Limited closer to the US market while also bolstering vertical integration, explains the firm’s managing director and CEO Siddharth Mittal in an exclusive interview about the new development.

In the second part of Generics Bulletin’s interview with Róbert Wessman, the Alvotech founder, chairman and CEO discusses global moves towards biosimilar streamlining – as well as talking PBMs, price negotiation, US trade tariffs and the push towards reshoring manufacturing.

In the first part of an exclusive two-part interview, Alvotech founder, chairman and CEO Róbert Wessman discusses key aspects of the rapidly-growing biosimilars developer’s strategy – while also explaining how the competitive landscape for biosimilars is evolving as originators get out of the game.

“We’ve invested billions of dollars and have achieved over $12bn in revenues since we launched our first biosimilars,” Amgen’s biosimilars head, Marc Doble, tells Generics Bulletin as part of an exclusive interview, which explores how the firm’s biosimilars benefit from its roots in biologics.

Centrient CEO Rex Clements talks about how the industry landscape is shifting for the European pure-play antibiotics producer, addressing issues including supply-chain security, US tariffs, localized manufacturing and AMR, as well as explaining how the firm is incorporating AI into its plans.

Academia spinout George Medicines snatched the first FDA approval for a triple combination pill for the initial treatment of hypertension. CEO Mark Mallon highlights the importance of partnering and what is next for the company.

In the wake of a major transaction that saw private-equity firm EQT take control of Alvo group B2B business Adalvo, CEO Anil Okay talks to Generics Bulletin about what the deal means for Adalvo and how it is planning to expand in future.

MENA specialist MS Pharma has been building up a portfolio of licensed biosimilars in recent years to build on its generics roots, seeking a first-mover advantage in key markets as well as benefiting from local manufacturing operations. Chief executive Kalle Känd sets out the firm’s strategy.

While biosimilars have seen success in Europe, there are still plenty of areas in which policy improvements could solve problems for the market, according to a new Samsung Bioepis white paper. Adam Levysohn, the firm’s local head of commercial strategy, talks about the proposals.